Vawter M P, Dillon-Carter O, Issa F, Wyatt R J, Freed W J
Section on Preclinical Neuroscience, NIMH Neuroscience Center at Saint Elizabeths, Washington, DC 20032, USA.
Neuropsychopharmacology. 1997 Jan;16(1):83-7. doi: 10.1016/S0893-133X(96)00143-1.
Transforming growth factor beta s (TGF beta s) are potent immunosuppressive molecules released in the brain after injury. We hypothesized that TGF beta levels in cerebrospinal fluid (CSF) of schizophrenic patients would be altered because TGF beta can influence neural cell adhesion molecule (N-CAM) expression in vitro. The levels of TGF beta 1 and beta 2 in CSF of patients with schizophrenia and normal controls measured by ELISA showed no differences. There was evidence that the stability of TGF beta in CSF may be altered in schizophrenia. For a limited sample, TGF beta 1 and N-CAM concentrations were significantly correlated in normal patients (r = 0.98) but not in schizophrenics. The results do not support an active neurodegeneration or anti-inflammatory response in the central nervous system, which is reflected in the CSF of chronic schizophrenics.
转化生长因子β(TGFβ)是损伤后在大脑中释放的强效免疫抑制分子。我们推测,精神分裂症患者脑脊液(CSF)中的TGFβ水平会发生改变,因为TGFβ在体外可影响神经细胞黏附分子(N-CAM)的表达。通过酶联免疫吸附测定法(ELISA)测量的精神分裂症患者和正常对照者脑脊液中TGFβ1和β2的水平没有差异。有证据表明,精神分裂症患者脑脊液中TGFβ的稳定性可能会发生改变。对于有限的样本,正常患者中TGFβ1和N-CAM浓度显著相关(r = 0.98),但精神分裂症患者中并非如此。这些结果不支持在慢性精神分裂症患者脑脊液中所反映出的中枢神经系统存在活跃的神经变性或抗炎反应。